IRVINE, Calif., July 28, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2022. Second Quarter Highlights and Outlook Q2 sales of $1.37 billion were flat versus an elevated prior year; underlying1 sales grew 5 percent Q2 TAVR sales […]
Tag: Edwards Lifesciences
EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
IRVINE, Calif., Jan. 26, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2021. Fourth Quarter Highlights and Outlook 2021 sales grew 19 percent, or 18 percent on an underlying1 basis Q4 sales grew 12 percent to $1.33 […]
Eisenhower Health First in California to Complete Edwards Benchmark™ Program for Transcatheter Aortic Valve Replacement (TAVR)
ONLY HOSPITAL IN COACHELLA VALLEY TO OFFER TAVR RANCHO MIRAGE, Calif., Dec. 16, 2021 /PRNewswire/ — Eisenhower Health is the FIRST hospital in California to be recognized by Edwards Lifesciences for completing its Edwards Benchmark program for the treatment of aortic stenosis in patients undergoing […]
Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program
IRVINE, Calif., Nov. 6, 2021 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) announced that results from a clinical trial of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated that favorable patient outcomes were sustained at six months. Results from the TRISCEND study, treating […]
TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis
IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost. This […]
Edwards Lifesciences Reports Third Quarter Results
IRVINE, Calif., Oct. 27, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2021. Third Quarter Highlights and 2021 Outlook Sales grew 15 percent to $1.3 billion; underlying1 sales grew 14 percent TAVR sales grew 15 percent; underlying 14 […]
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif., July 29, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2021. Second Quarter Highlights and 2021 Outlook Sales rebounded and grew 49 percent to $1.4 billion; underlying1 sales grew 44 percent TAVR sales exceeded expectations […]
Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff
IRVINE, Calif., June 1, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug Administration clearance. This is the first noninvasive solution that unlocks Acumen HPI […]
Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR
At 1 year, outcomes similar to overall cohort of patients IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 […]
Clinical Data Updates On Edwards’ Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR
IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that clinical results from the company’s transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at EuroPCR 2021, demonstrating positive outcomes for patients impacted by […]